Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 4273 - 4280 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCN2159 | 1,2,3,6-Tetragalloylglucose |
|
1. 1,2,3,6-Tetragalloylglucose has antioxidative activity.
2. 1,2,3,6-Tetragalloylglucose shows the most potent anticomplement activity (IC(50), 34 microM). |
|
| BCN2160 | Sodium barbital |
|
1. Sodium barbital was used as a model non-genotoxic renal carcinogen to test whether a concentration that increased renal tubular proliferation without severe nephrotoxicity would enhance tumor induction in a hereditary tumor model.
2. Sodium barbital causes progression to the stage of spontaneous renal lesions in Tsc2 mutant rats but do not increase their overall number. 3. Sodium barbital is a depressant of the central nervous system, has sedative/hypnotic effects. 4. Sodium barbital as an inhibitor of rabbit-muscle creatine kinase (CK), it might compete with both creatine and ATP, but mainly with creatine, to inhibit the activity of CK. 5. Sodium barbital is a tumour promoter, it can shorten the otherwise long latency between exposure to toxin and tumourigenesis. |
|
| BCN2162 | alpha-Chaconine |
|
1. Alpha-Chaconine has anti-inflammatory effect, associated with the suppression of AP-1, and supports its possible therapeutic role for the treatment of sepsis.
2. The cytotoxic effects of α-Solanine and alpha-Chaconine were observed immediately after incubation and were constant after 30min, suggesting that rapid damage of plasma membrane causes the lethal disorder of metabolism. |
|
| BCN2163 | Veraguensin |
|
1. Veraguensin shows activity against trypomastigote T. cruzi.
2. Veraguensin and galgravin can inhibit bone resorption and may offer novel compounds for the development of drugs to treat bone-destructive diseases such as osteoporosis. 3. Veraguensin shows high antileishmanial activity. |
|
| BCN2164 | Silodosin |
|
1. Silodosin, a selective α-1a receptor antagonist, can increase passage of distal ureteral stones.
2. Silodosin can temporarily improve lower urinary tract symptoms (LUTS), but do not improve the bladder outlet obstruction index (BOOI) after implantation in the prostate, it is a useful option for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia . 3. Silodosin appears to suppress ejaculation in a relatively higher percent of trial participants, this suppression of ejaculation by silodosin suggested its potential for treating premature ejaculation. |
|
| BCN2165 | Agomelatine |
|
Agomelatine is a competitive antagonist of human and porcine serotonin (5-HT2C) receptors (pKi = 6.2 and 6.4, respectively) as well as human 5-HT2B receptors (pKi = 6.6). Agomelatine is a melatonin (MT) analogue with agonistic properties and has been proven to be effective for various types of depressive symptoms, agomelatine also has anticonvulsant activity. Agomelatine treatment could represent a novel useful approach to the clinical care of subjects with Chronic Fatigue Syndrome (CFS). Agomelatine administration protects liver cells from paracetamol-induced hepatotoxicity via antioxidant activity and reduced proinflammatory cytokines, such as TNF-α and IL-6.
|
|
| BCN2166 | Rasagiline mesylate |
|
Rasagiline mesylate is a potent, selective, non-reversible MAO-B inhibitor, with neuroprotective activities, with anti-Parkinson activity. Rasagiline mesylate exhibits neuroprotective and anti-apoptotic activity against several neurotoxins in cell culture.
|
|
| BCN2167 | Fingolimod hydrochloride |
|
Fingolimod hydrochloride is an oral sphingosine-1-phosphate analogue that was approved by the FDA in 2010 for the treatment of relapsing forms of multiple sclerosis (MS). Fingolimod hydrochloride , a pak1 activator, can inhibit astemizole-induced hypertrophy and cytotoxicity in H9c2 cells, suggests that antihistamine-induced cardiac adverse effects are associated with pak1 expression and function.The gels containing 0.50% fingolimod hydrochloride (FNGL) and FNGL 0.50% plus 6% colloidal oatmeal have potential for the treatment of atopic dermatitis (AD).
|
|